RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with
- This topic has 0 replies, 1 voice, and was last updated 5 years, 7 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments
Complete response (i.e. disappearance of all target lesions and all non-target lesions) reported in U.S. patient with advanced gallbladder carcinoma treated with YELIVA® as part of RedHill’s Expanded Access Program, allowing compassionate use for eligible patients
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.